Aligned Genetics Inc (238120) — Capital Reinvestment Ratio
Latest as of June 2025:
0.24x
Aligned Genetics Inc (238120) has a Capital Reinvestment Ratio of 0.24x as of June 2025, meaning it reinvests 0% of its operating cash flow (₩677.20 Million) in capital expenditures (₩165.20 Million). See Aligned Genetics Inc (238120) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.24x
Capex / Operating Cash Flow
Operating Cash Flow
₩677.20 Million
KRW
Capital Expenditures
₩165.20 Million
KRW
Data as of
Jun 2025
Most recent filing
Aligned Genetics Inc Capital Reinvestment Ratio (2019–2024)
This chart tracks Aligned Genetics Inc's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Aligned Genetics Inc (2019–2024)
Year-by-year Capital Reinvestment Ratio for Aligned Genetics Inc from 2019 to 2024. For live market cap and broader valuation context, see 238120 company net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.11x | ₩3.07 Billion | ₩340.06 Million | ▼ -64.1% |
| 2023 | 0.31x | ₩2.85 Billion | ₩880.42 Million | ▼ -65.7% |
| 2022 | 0.90x | ₩2.22 Billion | ₩2.00 Billion | ▼ -96.3% |
| 2021 | 24.33x | ₩135.97 Million | ₩3.31 Billion | ▲ +799.8% |
| 2020 | 2.70x | ₩35.67 Million | ₩96.43 Million | ▲ +581.3% |
| 2019 | 0.40x | ₩659.29 Million | ₩261.62 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow